Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Rick Strange who wrote (81)	11/5/1998 2:48:00 AM
From: Richard Huth	Read Replies (1) \| Respond to of 1386

Rick You're right. My mistake. In this case it was BS. But approval in Europe is not in hands of PARS Mgt neither. To make myself clear. I personally have no doubt that the figures presented by Ariella will come that way. I only wanted to show a different point of view, how the things can be seen on first view by others. In a way buying a stock is no different from buying consumer goods. You look at quality and prices. But it does make a difference how the goods are presented. Will you be able to see quality on first or only on second view. What does look good on the first view is much easier to sell. And PARS does compete with other stocks in the market. In my opinion PARS is a quality stock with an excellent perspective. But actually it does not fit in investor's "excellent on first view" category. PARS' concept is different from the normally used one (i. concentrating on low risk/small market improved me-too products to generate revenue for R&D, than building up an interesting portfolio vs. concentrating on big market opportunities solely). I think PARS is doing right that way, but it is something new for the market. An other reason that might shy away an investor is the big number of shares outstanding. Together with the low stock price this can cause the fear of further dilution. Omer, Ariella et.al., not every new potential investor is as informed as you are. And for these investors it is not that easy to get the information base you have. A lot from what you know comes from direct talks to PARS Mgt. But not every new investor would call Mgt. (and btw, Mgt. has more important things to do than to talk to every potentiallly new investor themselves). Here PR has to tell the story. Richard